BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34767732)

  • 1. Silencing
    Xiao L; Peng H; Yan M; Chen S
    DNA Cell Biol; 2021 Nov; 40(11):1445-1455. PubMed ID: 34767732
    [No Abstract]   [Full Text] [Related]  

  • 2. The involvement of FBP1 in prostate cancer cell epithelial mesenchymal transition, invasion and metastasis by regulating the MAPK signaling pathway.
    Zhang YP; Liu KL; Yang Z; Lu BS; Qi JC; Han ZW; Yin YW; Zhang M; Chen DM; Wang XW; Li W; Xin H
    Cell Cycle; 2019 Oct; 18(19):2432-2446. PubMed ID: 31448674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition.
    Zhao Z; Zhao S; Luo L; Xiang Q; Zhu Z; Wang J; Liu Y; Luo J
    Br J Cancer; 2021 Mar; 124(5):982-994. PubMed ID: 33239676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RON and c-Met facilitate metastasis through the ERK signaling pathway in prostate cancer cells.
    Yin B; Liu Z; Wang Y; Wang X; Liu W; Yu P; Duan X; Liu C; Chen Y; Zhang Y; Pan X; Yao H; Liao Z; Tao Z
    Oncol Rep; 2017 Jun; 37(6):3209-3218. PubMed ID: 28440432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Over-expression of TM4SF1 improves cell metastasis and growth by activating ERK1/2 signaling pathway in human prostate cancer.
    Chen J; Wang F; Xu H; Chen D; Liu W; Wang J
    J BUON; 2019; 24(6):2531-2538. PubMed ID: 31983129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling.
    Wang B; Gu Y; Hui K; Huang J; Xu S; Wu S; Li L; Fan J; Wang X; Hsieh JT; He D; Wu K
    Urol Oncol; 2018 Oct; 36(10):472.e11-472.e20. PubMed ID: 30139661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer.
    Ding G; Fang J; Tong S; Qu L; Jiang H; Ding Q; Liu J
    Prostate; 2015 Jun; 75(9):957-68. PubMed ID: 25728945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mitogen-activated protein (MAP) kinases p38 and extracellular signal-regulated kinase (ERK) are involved in hepatocyte-mediated phenotypic switching in prostate cancer cells.
    Ma B; Wells A
    J Biol Chem; 2014 Apr; 289(16):11153-11161. PubMed ID: 24619413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the SPOCK1-snail/slug axis-mediated epithelial-to-mesenchymal transition by apigenin contributes to repression of prostate cancer metastasis.
    Chien MH; Lin YW; Wen YC; Yang YC; Hsiao M; Chang JL; Huang HC; Lee WJ
    J Exp Clin Cancer Res; 2019 Jun; 38(1):246. PubMed ID: 31182131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of long non-coding RNA PlncRNA-1 promotes proliferation and induces epithelial-mesenchymal transition in prostate cancer.
    Jin Y; Cui Z; Li X; Jin X; Peng J
    Oncotarget; 2017 Apr; 8(16):26090-26099. PubMed ID: 28212533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA VIM-AS1 promotes prostate cancer growth and invasion by regulating epithelial-mesenchymal transition.
    Zhang Y; Zhang J; Liang S; Lang G; Liu G; Liu P; Deng X
    J BUON; 2019; 24(5):2090-2098. PubMed ID: 31786880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer.
    Hance MW; Dole K; Gopal U; Bohonowych JE; Jezierska-Drutel A; Neumann CA; Liu H; Garraway IP; Isaacs JS
    J Biol Chem; 2012 Nov; 287(45):37732-44. PubMed ID: 22989880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aphthous ulcer drug inhibits prostate tumor metastasis by targeting IKKɛ/TBK1/NF-κB signaling.
    Cheng C; Ji Z; Sheng Y; Wang J; Sun Y; Zhao H; Li X; Wang X; He Y; Yao J; Wang L; Zhang C; Guo Y; Zhang J; Gao WQ; Zhu HH
    Theranostics; 2018; 8(17):4633-4648. PubMed ID: 30279728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevation of androgen receptor promotes prostate cancer metastasis by induction of epithelial-mesenchymal transition and reduction of KAT5.
    Lin CY; Jan YJ; Kuo LK; Wang BJ; Huo C; Jiang SS; Chen SC; Kuo YY; Chang CR; Chuu CP
    Cancer Sci; 2018 Nov; 109(11):3564-3574. PubMed ID: 30142696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of hSef promotes metastasis through upregulation of EMT in prostate cancer.
    Hori S; Wadhwa K; Pisupati V; Zecchini V; Ramos-Montoya A; Warren AY; Neal DE; Gnanapragasam VJ
    Int J Cancer; 2017 Apr; 140(8):1881-1887. PubMed ID: 28073170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SOX4 is associated with poor prognosis in prostate cancer and promotes epithelial-mesenchymal transition in vitro.
    Wang L; Zhang J; Yang X; Chang YW; Qi M; Zhou Z; Zhang J; Han B
    Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):301-7. PubMed ID: 23917306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ROR2 suppresses metastasis of prostate cancer via regulation of miR-199a-5p-PIAS3-AKT2 signaling axis.
    Tseng JC; Huang SH; Lin CY; Wang BJ; Huang SF; Shen YY; Chuu CP
    Cell Death Dis; 2020 May; 11(5):376. PubMed ID: 32415173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIC1 loss promotes prostate cancer metastasis by triggering epithelial-mesenchymal transition.
    Hao M; Li Y; Wang J; Qin J; Wang Y; Ding Y; Jiang M; Sun X; Zu L; Chang K; Lin G; Du J; Korinek V; Ye DW; Wang J
    J Pathol; 2017 Aug; 242(4):409-420. PubMed ID: 28466555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TERF1 downregulation promotes the migration and invasion of the PC3 prostate cancer cell line as a target of miR‑155.
    Chen W; He LN; Liang Y; Zeng X; Wu CP; Su MQ; Cheng Y; Liu JH
    Mol Med Rep; 2020 Dec; 22(6):5209-5218. PubMed ID: 33174061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
    Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
    Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.